nodes	percent_of_prediction	percent_of_DWPC	metapath
Bortezomib—CYP1A2—Imiquimod—skin cancer	0.0615	0.122	CbGbCtD
Bortezomib—CYP1A1—Dacarbazine—skin cancer	0.0578	0.114	CbGbCtD
Bortezomib—CYP2C8—Vismodegib—skin cancer	0.0551	0.109	CbGbCtD
Bortezomib—CYP2C19—Vismodegib—skin cancer	0.0462	0.0915	CbGbCtD
Bortezomib—CYP2C9—Vismodegib—skin cancer	0.0384	0.076	CbGbCtD
Bortezomib—CYP1A2—Vemurafenib—skin cancer	0.0337	0.0667	CbGbCtD
Bortezomib—CYP3A4—Imiquimod—skin cancer	0.0322	0.0638	CbGbCtD
Bortezomib—CYP3A4—Temozolomide—skin cancer	0.0322	0.0638	CbGbCtD
Bortezomib—CYP2D6—Vemurafenib—skin cancer	0.0278	0.055	CbGbCtD
Bortezomib—CYP1A2—Dacarbazine—skin cancer	0.0258	0.0511	CbGbCtD
Bortezomib—CYP3A4—Vismodegib—skin cancer	0.0223	0.0442	CbGbCtD
Bortezomib—CYP2C8—Fluorouracil—skin cancer	0.0196	0.0387	CbGbCtD
Bortezomib—CYP3A4—Vemurafenib—skin cancer	0.0177	0.035	CbGbCtD
Bortezomib—CYP1A2—Fluorouracil—skin cancer	0.0151	0.03	CbGbCtD
Bortezomib—CYP2C9—Fluorouracil—skin cancer	0.0136	0.027	CbGbCtD
Bortezomib—CYP3A4—Docetaxel—skin cancer	0.00606	0.012	CbGbCtD
Bortezomib—PSMD1—hair follicle—skin cancer	0.00463	0.0407	CbGeAlD
Bortezomib—PSMD2—Sorafenib—Vismodegib—skin cancer	0.00446	1	CbGdCrCtD
Bortezomib—PSMB2—skin epidermis—skin cancer	0.0043	0.0378	CbGeAlD
Bortezomib—PSMD2—hair follicle—skin cancer	0.0041	0.0361	CbGeAlD
Bortezomib—CTSG—nipple—skin cancer	0.00389	0.0342	CbGeAlD
Bortezomib—PSMB5—hair follicle—skin cancer	0.0036	0.0317	CbGeAlD
Bortezomib—PSMB1—hair follicle—skin cancer	0.00315	0.0277	CbGeAlD
Bortezomib—PSMD1—nipple—skin cancer	0.00314	0.0276	CbGeAlD
Bortezomib—PSMB2—hair follicle—skin cancer	0.00307	0.027	CbGeAlD
Bortezomib—PSMD2—nipple—skin cancer	0.00278	0.0244	CbGeAlD
Bortezomib—PSMB8—nipple—skin cancer	0.00276	0.0243	CbGeAlD
Bortezomib—CTSG—connective tissue—skin cancer	0.00276	0.0243	CbGeAlD
Bortezomib—SLC31A1—hair follicle—skin cancer	0.00266	0.0234	CbGeAlD
Bortezomib—PSMA1—connective tissue—skin cancer	0.00265	0.0233	CbGeAlD
Bortezomib—PSMA1—epithelium—skin cancer	0.00252	0.0221	CbGeAlD
Bortezomib—CTSG—skin of body—skin cancer	0.00249	0.0219	CbGeAlD
Bortezomib—PSMB5—nipple—skin cancer	0.00244	0.0215	CbGeAlD
Bortezomib—PSMA1—skin of body—skin cancer	0.00239	0.021	CbGeAlD
Bortezomib—CTSG—mammalian vulva—skin cancer	0.00227	0.02	CbGeAlD
Bortezomib—Lacosamide—SCN10A—skin cancer	0.00223	1	CrCbGaD
Bortezomib—PSMB1—nipple—skin cancer	0.00213	0.0188	CbGeAlD
Bortezomib—PSMB2—nipple—skin cancer	0.00208	0.0183	CbGeAlD
Bortezomib—CTSG—lymphoid tissue—skin cancer	0.00202	0.0178	CbGeAlD
Bortezomib—PSMA1—lymphoid tissue—skin cancer	0.00194	0.017	CbGeAlD
Bortezomib—PSMA1—female reproductive system—skin cancer	0.00187	0.0164	CbGeAlD
Bortezomib—PSMD1—mammalian vulva—skin cancer	0.00183	0.0161	CbGeAlD
Bortezomib—SLC31A1—nipple—skin cancer	0.0018	0.0158	CbGeAlD
Bortezomib—PSMD2—skin of body—skin cancer	0.00178	0.0157	CbGeAlD
Bortezomib—PSMD2—mammalian vulva—skin cancer	0.00162	0.0143	CbGeAlD
Bortezomib—PSMB8—mammalian vulva—skin cancer	0.00161	0.0142	CbGeAlD
Bortezomib—PSMA1—head—skin cancer	0.00156	0.0137	CbGeAlD
Bortezomib—PSMB2—connective tissue—skin cancer	0.00148	0.013	CbGeAlD
Bortezomib—PSMD2—lymphoid tissue—skin cancer	0.00144	0.0127	CbGeAlD
Bortezomib—PSMB5—mammalian vulva—skin cancer	0.00143	0.0125	CbGeAlD
Bortezomib—PSMD2—female reproductive system—skin cancer	0.00139	0.0122	CbGeAlD
Bortezomib—PSMB1—skin of body—skin cancer	0.00137	0.012	CbGeAlD
Bortezomib—PSMB2—skin of body—skin cancer	0.00133	0.0117	CbGeAlD
Bortezomib—CYP1A1—skin epidermis—skin cancer	0.00127	0.0111	CbGeAlD
Bortezomib—PSMB1—mammalian vulva—skin cancer	0.00125	0.011	CbGeAlD
Bortezomib—PSMB2—mammalian vulva—skin cancer	0.00122	0.0107	CbGeAlD
Bortezomib—PSMD2—head—skin cancer	0.00116	0.0102	CbGeAlD
Bortezomib—CTSG—lymph node—skin cancer	0.00114	0.01	CbGeAlD
Bortezomib—PSMB1—lymphoid tissue—skin cancer	0.00111	0.00973	CbGeAlD
Bortezomib—PSMA1—lymph node—skin cancer	0.00109	0.00962	CbGeAlD
Bortezomib—PSMB2—lymphoid tissue—skin cancer	0.00108	0.00949	CbGeAlD
Bortezomib—PSMB1—female reproductive system—skin cancer	0.00107	0.00938	CbGeAlD
Bortezomib—SLC31A1—mammalian vulva—skin cancer	0.00105	0.00926	CbGeAlD
Bortezomib—PSMB2—female reproductive system—skin cancer	0.00104	0.00915	CbGeAlD
Bortezomib—PSMD1—lymph node—skin cancer	0.000918	0.00807	CbGeAlD
Bortezomib—SLC31A1—female reproductive system—skin cancer	0.000901	0.00793	CbGeAlD
Bortezomib—PSMB1—head—skin cancer	0.000891	0.00784	CbGeAlD
Bortezomib—PSMB2—head—skin cancer	0.00087	0.00765	CbGeAlD
Bortezomib—PSMD2—lymph node—skin cancer	0.000813	0.00715	CbGeAlD
Bortezomib—PSMB8—lymph node—skin cancer	0.000808	0.00711	CbGeAlD
Bortezomib—PTGS1—endothelium—skin cancer	0.000807	0.00709	CbGeAlD
Bortezomib—SLC31A1—head—skin cancer	0.000753	0.00662	CbGeAlD
Bortezomib—PTGS1—blood vessel—skin cancer	0.000744	0.00654	CbGeAlD
Bortezomib—PSMB5—lymph node—skin cancer	0.000714	0.00628	CbGeAlD
Bortezomib—PSMB1—lymph node—skin cancer	0.000624	0.00549	CbGeAlD
Bortezomib—CYP1A2—nipple—skin cancer	0.00062	0.00546	CbGeAlD
Bortezomib—CYP1A1—nipple—skin cancer	0.000612	0.00538	CbGeAlD
Bortezomib—PSMB2—lymph node—skin cancer	0.000609	0.00535	CbGeAlD
Bortezomib—PTGS1—nipple—skin cancer	0.000538	0.00473	CbGeAlD
Bortezomib—SLC31A1—lymph node—skin cancer	0.000527	0.00464	CbGeAlD
Bortezomib—CYP1A1—epithelium—skin cancer	0.000412	0.00362	CbGeAlD
Bortezomib—CYP1A1—skin of body—skin cancer	0.000392	0.00345	CbGeAlD
Bortezomib—PTGS1—connective tissue—skin cancer	0.000381	0.00335	CbGeAlD
Bortezomib—PTGS1—epithelium—skin cancer	0.000362	0.00318	CbGeAlD
Bortezomib—CYP1A1—mammalian vulva—skin cancer	0.000357	0.00314	CbGeAlD
Bortezomib—PTGS1—skin of body—skin cancer	0.000344	0.00303	CbGeAlD
Bortezomib—CYP2C8—female reproductive system—skin cancer	0.000332	0.00292	CbGeAlD
Bortezomib—PTGS1—mammalian vulva—skin cancer	0.000314	0.00276	CbGeAlD
Bortezomib—CYP1A1—female reproductive system—skin cancer	0.000306	0.00269	CbGeAlD
Bortezomib—CYP2C9—female reproductive system—skin cancer	0.000295	0.00259	CbGeAlD
Bortezomib—PTGS1—female reproductive system—skin cancer	0.000269	0.00237	CbGeAlD
Bortezomib—CYP1A1—head—skin cancer	0.000256	0.00225	CbGeAlD
Bortezomib—PTGS1—head—skin cancer	0.000225	0.00198	CbGeAlD
Bortezomib—CYP3A4—female reproductive system—skin cancer	0.000225	0.00198	CbGeAlD
Bortezomib—CYP2D6—female reproductive system—skin cancer	0.000221	0.00194	CbGeAlD
Bortezomib—CYP2D6—head—skin cancer	0.000185	0.00162	CbGeAlD
Bortezomib—CYP1A1—lymph node—skin cancer	0.000179	0.00158	CbGeAlD
Bortezomib—PTGS1—lymph node—skin cancer	0.000157	0.00138	CbGeAlD
Bortezomib—Orthostatic hypotension—Docetaxel—skin cancer	0.000128	0.000531	CcSEcCtD
Bortezomib—Abdominal pain upper—Docetaxel—skin cancer	0.000128	0.000531	CcSEcCtD
Bortezomib—Rash—Vemurafenib—skin cancer	0.000128	0.00053	CcSEcCtD
Bortezomib—Mental disorder—Temozolomide—skin cancer	0.000128	0.00053	CcSEcCtD
Bortezomib—Dermatitis—Vemurafenib—skin cancer	0.000128	0.00053	CcSEcCtD
Bortezomib—Hypersensitivity—Imiquimod—skin cancer	0.000127	0.000528	CcSEcCtD
Bortezomib—Headache—Vemurafenib—skin cancer	0.000127	0.000527	CcSEcCtD
Bortezomib—Malnutrition—Temozolomide—skin cancer	0.000127	0.000526	CcSEcCtD
Bortezomib—Erythema—Temozolomide—skin cancer	0.000127	0.000526	CcSEcCtD
Bortezomib—Breast disorder—Docetaxel—skin cancer	0.000127	0.000525	CcSEcCtD
Bortezomib—Discomfort—Bleomycin—skin cancer	0.000127	0.000525	CcSEcCtD
Bortezomib—Malaise—Dactinomycin—skin cancer	0.000127	0.000525	CcSEcCtD
Bortezomib—Cramp muscle—Docetaxel—skin cancer	0.000126	0.000524	CcSEcCtD
Bortezomib—Toxic epidermal necrolysis—Docetaxel—skin cancer	0.000126	0.000524	CcSEcCtD
Bortezomib—Leukopenia—Dactinomycin—skin cancer	0.000126	0.000521	CcSEcCtD
Bortezomib—Nasopharyngitis—Docetaxel—skin cancer	0.000125	0.00052	CcSEcCtD
Bortezomib—Dysgeusia—Temozolomide—skin cancer	0.000124	0.000516	CcSEcCtD
Bortezomib—Asthenia—Imiquimod—skin cancer	0.000124	0.000514	CcSEcCtD
Bortezomib—Confusional state—Bleomycin—skin cancer	0.000124	0.000514	CcSEcCtD
Bortezomib—Anaphylactic shock—Bleomycin—skin cancer	0.000123	0.000509	CcSEcCtD
Bortezomib—Oedema—Bleomycin—skin cancer	0.000123	0.000509	CcSEcCtD
Bortezomib—Back pain—Temozolomide—skin cancer	0.000123	0.000509	CcSEcCtD
Bortezomib—Pruritus—Imiquimod—skin cancer	0.000122	0.000507	CcSEcCtD
Bortezomib—Infection—Bleomycin—skin cancer	0.000122	0.000506	CcSEcCtD
Bortezomib—Dysphagia—Docetaxel—skin cancer	0.000121	0.000502	CcSEcCtD
Bortezomib—Nausea—Vemurafenib—skin cancer	0.00012	0.000499	CcSEcCtD
Bortezomib—Thrombocytopenia—Bleomycin—skin cancer	0.00012	0.000499	CcSEcCtD
Bortezomib—Arrhythmia—Fluorouracil—skin cancer	0.00012	0.000498	CcSEcCtD
Bortezomib—Vision blurred—Temozolomide—skin cancer	0.00012	0.000496	CcSEcCtD
Bortezomib—Myalgia—Dactinomycin—skin cancer	0.00012	0.000496	CcSEcCtD
Bortezomib—Bronchospasm—Docetaxel—skin cancer	0.000119	0.000494	CcSEcCtD
Bortezomib—Tremor—Temozolomide—skin cancer	0.000119	0.000493	CcSEcCtD
Bortezomib—Diarrhoea—Imiquimod—skin cancer	0.000118	0.000491	CcSEcCtD
Bortezomib—Discomfort—Dactinomycin—skin cancer	0.000118	0.00049	CcSEcCtD
Bortezomib—Angina pectoris—Docetaxel—skin cancer	0.000118	0.000489	CcSEcCtD
Bortezomib—Ill-defined disorder—Temozolomide—skin cancer	0.000118	0.000488	CcSEcCtD
Bortezomib—Anaemia—Temozolomide—skin cancer	0.000117	0.000487	CcSEcCtD
Bortezomib—Anorexia—Bleomycin—skin cancer	0.000117	0.000486	CcSEcCtD
Bortezomib—Erythema—Fluorouracil—skin cancer	0.000117	0.000485	CcSEcCtD
Bortezomib—Agitation—Temozolomide—skin cancer	0.000117	0.000484	CcSEcCtD
Bortezomib—Angioedema—Temozolomide—skin cancer	0.000116	0.000481	CcSEcCtD
Bortezomib—Pancytopenia—Docetaxel—skin cancer	0.000115	0.000477	CcSEcCtD
Bortezomib—Hypotension—Bleomycin—skin cancer	0.000115	0.000476	CcSEcCtD
Bortezomib—Oedema—Dactinomycin—skin cancer	0.000115	0.000475	CcSEcCtD
Bortezomib—Malaise—Temozolomide—skin cancer	0.000114	0.000475	CcSEcCtD
Bortezomib—Dizziness—Imiquimod—skin cancer	0.000114	0.000474	CcSEcCtD
Bortezomib—Vertigo—Temozolomide—skin cancer	0.000114	0.000473	CcSEcCtD
Bortezomib—Infection—Dactinomycin—skin cancer	0.000114	0.000472	CcSEcCtD
Bortezomib—Leukopenia—Temozolomide—skin cancer	0.000114	0.000471	CcSEcCtD
Bortezomib—Neutropenia—Docetaxel—skin cancer	0.000113	0.00047	CcSEcCtD
Bortezomib—Palpitations—Temozolomide—skin cancer	0.000112	0.000465	CcSEcCtD
Bortezomib—Thrombocytopenia—Dactinomycin—skin cancer	0.000112	0.000465	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Bleomycin—skin cancer	0.000112	0.000464	CcSEcCtD
Bortezomib—Cough—Temozolomide—skin cancer	0.000111	0.000459	CcSEcCtD
Bortezomib—Paraesthesia—Bleomycin—skin cancer	0.00011	0.000457	CcSEcCtD
Bortezomib—Weight increased—Docetaxel—skin cancer	0.00011	0.000457	CcSEcCtD
Bortezomib—Vision blurred—Fluorouracil—skin cancer	0.00011	0.000457	CcSEcCtD
Bortezomib—Convulsion—Temozolomide—skin cancer	0.00011	0.000456	CcSEcCtD
Bortezomib—Vomiting—Imiquimod—skin cancer	0.00011	0.000456	CcSEcCtD
Bortezomib—Weight decreased—Docetaxel—skin cancer	0.00011	0.000455	CcSEcCtD
Bortezomib—Hypertension—Temozolomide—skin cancer	0.00011	0.000455	CcSEcCtD
Bortezomib—Dyspnoea—Bleomycin—skin cancer	0.00011	0.000454	CcSEcCtD
Bortezomib—Anorexia—Dactinomycin—skin cancer	0.000109	0.000453	CcSEcCtD
Bortezomib—Rash—Imiquimod—skin cancer	0.000109	0.000452	CcSEcCtD
Bortezomib—Dermatitis—Imiquimod—skin cancer	0.000109	0.000452	CcSEcCtD
Bortezomib—Pneumonia—Docetaxel—skin cancer	0.000109	0.000451	CcSEcCtD
Bortezomib—Headache—Imiquimod—skin cancer	0.000108	0.000449	CcSEcCtD
Bortezomib—Anaemia—Fluorouracil—skin cancer	0.000108	0.000448	CcSEcCtD
Bortezomib—Arthralgia—Temozolomide—skin cancer	0.000108	0.000448	CcSEcCtD
Bortezomib—Myalgia—Temozolomide—skin cancer	0.000108	0.000448	CcSEcCtD
Bortezomib—Infestation NOS—Docetaxel—skin cancer	0.000108	0.000448	CcSEcCtD
Bortezomib—Infestation—Docetaxel—skin cancer	0.000108	0.000448	CcSEcCtD
Bortezomib—Anxiety—Temozolomide—skin cancer	0.000108	0.000447	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.000107	0.000445	CcSEcCtD
Bortezomib—Stevens-Johnson syndrome—Docetaxel—skin cancer	0.000107	0.000444	CcSEcCtD
Bortezomib—Discomfort—Temozolomide—skin cancer	0.000107	0.000443	CcSEcCtD
Bortezomib—Decreased appetite—Bleomycin—skin cancer	0.000107	0.000443	CcSEcCtD
Bortezomib—Acute coronary syndrome—Docetaxel—skin cancer	0.000107	0.000442	CcSEcCtD
Bortezomib—Renal failure—Docetaxel—skin cancer	0.000106	0.00044	CcSEcCtD
Bortezomib—Neuropathy peripheral—Docetaxel—skin cancer	0.000106	0.000439	CcSEcCtD
Bortezomib—Myocardial infarction—Docetaxel—skin cancer	0.000106	0.000439	CcSEcCtD
Bortezomib—Stomatitis—Docetaxel—skin cancer	0.000105	0.000437	CcSEcCtD
Bortezomib—Pain—Bleomycin—skin cancer	0.000105	0.000436	CcSEcCtD
Bortezomib—Conjunctivitis—Docetaxel—skin cancer	0.000105	0.000435	CcSEcCtD
Bortezomib—Leukopenia—Fluorouracil—skin cancer	0.000105	0.000434	CcSEcCtD
Bortezomib—Confusional state—Temozolomide—skin cancer	0.000104	0.000433	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.000104	0.000433	CcSEcCtD
Bortezomib—Anaphylactic shock—Temozolomide—skin cancer	0.000104	0.00043	CcSEcCtD
Bortezomib—Oedema—Temozolomide—skin cancer	0.000104	0.00043	CcSEcCtD
Bortezomib—Infection—Temozolomide—skin cancer	0.000103	0.000427	CcSEcCtD
Bortezomib—Nausea—Imiquimod—skin cancer	0.000103	0.000426	CcSEcCtD
Bortezomib—Hepatobiliary disease—Docetaxel—skin cancer	0.000102	0.000424	CcSEcCtD
Bortezomib—Epistaxis—Docetaxel—skin cancer	0.000102	0.000423	CcSEcCtD
Bortezomib—Nervous system disorder—Temozolomide—skin cancer	0.000102	0.000421	CcSEcCtD
Bortezomib—Thrombocytopenia—Temozolomide—skin cancer	0.000101	0.000421	CcSEcCtD
Bortezomib—Convulsion—Fluorouracil—skin cancer	0.000101	0.00042	CcSEcCtD
Bortezomib—Feeling abnormal—Bleomycin—skin cancer	0.000101	0.00042	CcSEcCtD
Bortezomib—Skin disorder—Temozolomide—skin cancer	0.000101	0.000417	CcSEcCtD
Bortezomib—Hyperhidrosis—Temozolomide—skin cancer	0.0001	0.000415	CcSEcCtD
Bortezomib—Myalgia—Fluorouracil—skin cancer	9.96e-05	0.000413	CcSEcCtD
Bortezomib—Chest pain—Fluorouracil—skin cancer	9.96e-05	0.000413	CcSEcCtD
Bortezomib—Decreased appetite—Dactinomycin—skin cancer	9.96e-05	0.000413	CcSEcCtD
Bortezomib—Fatigue—Dactinomycin—skin cancer	9.88e-05	0.00041	CcSEcCtD
Bortezomib—Anorexia—Temozolomide—skin cancer	9.88e-05	0.00041	CcSEcCtD
Bortezomib—Discomfort—Fluorouracil—skin cancer	9.84e-05	0.000408	CcSEcCtD
Bortezomib—Pain—Dactinomycin—skin cancer	9.8e-05	0.000406	CcSEcCtD
Bortezomib—Urticaria—Bleomycin—skin cancer	9.76e-05	0.000405	CcSEcCtD
Bortezomib—Haemoglobin—Docetaxel—skin cancer	9.75e-05	0.000404	CcSEcCtD
Bortezomib—Body temperature increased—Bleomycin—skin cancer	9.71e-05	0.000403	CcSEcCtD
Bortezomib—Haemorrhage—Docetaxel—skin cancer	9.7e-05	0.000402	CcSEcCtD
Bortezomib—Hepatitis—Docetaxel—skin cancer	9.7e-05	0.000402	CcSEcCtD
Bortezomib—Hypoaesthesia—Docetaxel—skin cancer	9.65e-05	0.0004	CcSEcCtD
Bortezomib—Confusional state—Fluorouracil—skin cancer	9.63e-05	0.000399	CcSEcCtD
Bortezomib—Urinary tract disorder—Docetaxel—skin cancer	9.58e-05	0.000397	CcSEcCtD
Bortezomib—Oedema peripheral—Docetaxel—skin cancer	9.55e-05	0.000396	CcSEcCtD
Bortezomib—Oedema—Fluorouracil—skin cancer	9.55e-05	0.000396	CcSEcCtD
Bortezomib—Anaphylactic shock—Fluorouracil—skin cancer	9.55e-05	0.000396	CcSEcCtD
Bortezomib—Connective tissue disorder—Docetaxel—skin cancer	9.53e-05	0.000395	CcSEcCtD
Bortezomib—Urethral disorder—Docetaxel—skin cancer	9.51e-05	0.000394	CcSEcCtD
Bortezomib—Infection—Fluorouracil—skin cancer	9.48e-05	0.000393	CcSEcCtD
Bortezomib—Feeling abnormal—Dactinomycin—skin cancer	9.44e-05	0.000391	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Temozolomide—skin cancer	9.44e-05	0.000391	CcSEcCtD
Bortezomib—Insomnia—Temozolomide—skin cancer	9.37e-05	0.000389	CcSEcCtD
Bortezomib—Gastrointestinal pain—Dactinomycin—skin cancer	9.37e-05	0.000388	CcSEcCtD
Bortezomib—Nervous system disorder—Fluorouracil—skin cancer	9.36e-05	0.000388	CcSEcCtD
Bortezomib—Thrombocytopenia—Fluorouracil—skin cancer	9.35e-05	0.000388	CcSEcCtD
Bortezomib—Visual impairment—Docetaxel—skin cancer	9.35e-05	0.000388	CcSEcCtD
Bortezomib—Tachycardia—Fluorouracil—skin cancer	9.32e-05	0.000386	CcSEcCtD
Bortezomib—Paraesthesia—Temozolomide—skin cancer	9.3e-05	0.000386	CcSEcCtD
Bortezomib—Dyspnoea—Temozolomide—skin cancer	9.24e-05	0.000383	CcSEcCtD
Bortezomib—Erythema multiforme—Docetaxel—skin cancer	9.17e-05	0.00038	CcSEcCtD
Bortezomib—Dyspepsia—Temozolomide—skin cancer	9.12e-05	0.000378	CcSEcCtD
Bortezomib—Anorexia—Fluorouracil—skin cancer	9.1e-05	0.000377	CcSEcCtD
Bortezomib—Eye disorder—Docetaxel—skin cancer	9.06e-05	0.000376	CcSEcCtD
Bortezomib—Body temperature increased—Dactinomycin—skin cancer	9.06e-05	0.000376	CcSEcCtD
Bortezomib—Abdominal pain—Dactinomycin—skin cancer	9.06e-05	0.000376	CcSEcCtD
Bortezomib—Hypersensitivity—Bleomycin—skin cancer	9.05e-05	0.000375	CcSEcCtD
Bortezomib—Decreased appetite—Temozolomide—skin cancer	9.01e-05	0.000374	CcSEcCtD
Bortezomib—Cardiac disorder—Docetaxel—skin cancer	9e-05	0.000373	CcSEcCtD
Bortezomib—Flushing—Docetaxel—skin cancer	9e-05	0.000373	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Temozolomide—skin cancer	8.95e-05	0.000371	CcSEcCtD
Bortezomib—Fatigue—Temozolomide—skin cancer	8.93e-05	0.00037	CcSEcCtD
Bortezomib—Hypotension—Fluorouracil—skin cancer	8.92e-05	0.00037	CcSEcCtD
Bortezomib—Constipation—Temozolomide—skin cancer	8.86e-05	0.000367	CcSEcCtD
Bortezomib—Pain—Temozolomide—skin cancer	8.86e-05	0.000367	CcSEcCtD
Bortezomib—Asthenia—Bleomycin—skin cancer	8.81e-05	0.000365	CcSEcCtD
Bortezomib—Angiopathy—Docetaxel—skin cancer	8.8e-05	0.000365	CcSEcCtD
Bortezomib—Immune system disorder—Docetaxel—skin cancer	8.76e-05	0.000363	CcSEcCtD
Bortezomib—Mediastinal disorder—Docetaxel—skin cancer	8.74e-05	0.000362	CcSEcCtD
Bortezomib—Chills—Docetaxel—skin cancer	8.7e-05	0.000361	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Fluorouracil—skin cancer	8.7e-05	0.000361	CcSEcCtD
Bortezomib—Pruritus—Bleomycin—skin cancer	8.69e-05	0.00036	CcSEcCtD
Bortezomib—Arrhythmia—Docetaxel—skin cancer	8.66e-05	0.000359	CcSEcCtD
Bortezomib—Insomnia—Fluorouracil—skin cancer	8.63e-05	0.000358	CcSEcCtD
Bortezomib—Paraesthesia—Fluorouracil—skin cancer	8.57e-05	0.000355	CcSEcCtD
Bortezomib—Feeling abnormal—Temozolomide—skin cancer	8.54e-05	0.000354	CcSEcCtD
Bortezomib—Dyspnoea—Fluorouracil—skin cancer	8.51e-05	0.000353	CcSEcCtD
Bortezomib—Mental disorder—Docetaxel—skin cancer	8.5e-05	0.000352	CcSEcCtD
Bortezomib—Gastrointestinal pain—Temozolomide—skin cancer	8.47e-05	0.000351	CcSEcCtD
Bortezomib—Erythema—Docetaxel—skin cancer	8.44e-05	0.00035	CcSEcCtD
Bortezomib—Malnutrition—Docetaxel—skin cancer	8.44e-05	0.00035	CcSEcCtD
Bortezomib—Hypersensitivity—Dactinomycin—skin cancer	8.44e-05	0.00035	CcSEcCtD
Bortezomib—Dyspepsia—Fluorouracil—skin cancer	8.4e-05	0.000348	CcSEcCtD
Bortezomib—Decreased appetite—Fluorouracil—skin cancer	8.3e-05	0.000344	CcSEcCtD
Bortezomib—Dysgeusia—Docetaxel—skin cancer	8.27e-05	0.000343	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Fluorouracil—skin cancer	8.24e-05	0.000342	CcSEcCtD
Bortezomib—Urticaria—Temozolomide—skin cancer	8.23e-05	0.000341	CcSEcCtD
Bortezomib—Asthenia—Dactinomycin—skin cancer	8.22e-05	0.000341	CcSEcCtD
Bortezomib—Body temperature increased—Temozolomide—skin cancer	8.19e-05	0.00034	CcSEcCtD
Bortezomib—Abdominal pain—Temozolomide—skin cancer	8.19e-05	0.00034	CcSEcCtD
Bortezomib—Back pain—Docetaxel—skin cancer	8.17e-05	0.000339	CcSEcCtD
Bortezomib—Pain—Fluorouracil—skin cancer	8.16e-05	0.000339	CcSEcCtD
Bortezomib—Muscle spasms—Docetaxel—skin cancer	8.12e-05	0.000337	CcSEcCtD
Bortezomib—Feeling abnormal—Fluorouracil—skin cancer	7.87e-05	0.000326	CcSEcCtD
Bortezomib—Diarrhoea—Dactinomycin—skin cancer	7.84e-05	0.000325	CcSEcCtD
Bortezomib—Vomiting—Bleomycin—skin cancer	7.81e-05	0.000324	CcSEcCtD
Bortezomib—Anaemia—Docetaxel—skin cancer	7.8e-05	0.000324	CcSEcCtD
Bortezomib—Rash—Bleomycin—skin cancer	7.74e-05	0.000321	CcSEcCtD
Bortezomib—Dermatitis—Bleomycin—skin cancer	7.74e-05	0.000321	CcSEcCtD
Bortezomib—Hypersensitivity—Temozolomide—skin cancer	7.63e-05	0.000317	CcSEcCtD
Bortezomib—Urticaria—Fluorouracil—skin cancer	7.58e-05	0.000315	CcSEcCtD
Bortezomib—Syncope—Docetaxel—skin cancer	7.57e-05	0.000314	CcSEcCtD
Bortezomib—Leukopenia—Docetaxel—skin cancer	7.56e-05	0.000313	CcSEcCtD
Bortezomib—Body temperature increased—Fluorouracil—skin cancer	7.55e-05	0.000313	CcSEcCtD
Bortezomib—Palpitations—Docetaxel—skin cancer	7.46e-05	0.000309	CcSEcCtD
Bortezomib—Asthenia—Temozolomide—skin cancer	7.43e-05	0.000308	CcSEcCtD
Bortezomib—Loss of consciousness—Docetaxel—skin cancer	7.42e-05	0.000308	CcSEcCtD
Bortezomib—Cough—Docetaxel—skin cancer	7.37e-05	0.000306	CcSEcCtD
Bortezomib—Pruritus—Temozolomide—skin cancer	7.33e-05	0.000304	CcSEcCtD
Bortezomib—Convulsion—Docetaxel—skin cancer	7.32e-05	0.000303	CcSEcCtD
Bortezomib—Nausea—Bleomycin—skin cancer	7.3e-05	0.000303	CcSEcCtD
Bortezomib—Hypertension—Docetaxel—skin cancer	7.29e-05	0.000302	CcSEcCtD
Bortezomib—Vomiting—Dactinomycin—skin cancer	7.28e-05	0.000302	CcSEcCtD
Bortezomib—Rash—Dactinomycin—skin cancer	7.22e-05	0.0003	CcSEcCtD
Bortezomib—Myalgia—Docetaxel—skin cancer	7.19e-05	0.000298	CcSEcCtD
Bortezomib—Chest pain—Docetaxel—skin cancer	7.19e-05	0.000298	CcSEcCtD
Bortezomib—Arthralgia—Docetaxel—skin cancer	7.19e-05	0.000298	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	7.14e-05	0.000296	CcSEcCtD
Bortezomib—Diarrhoea—Temozolomide—skin cancer	7.09e-05	0.000294	CcSEcCtD
Bortezomib—Hypersensitivity—Fluorouracil—skin cancer	7.03e-05	0.000292	CcSEcCtD
Bortezomib—Confusional state—Docetaxel—skin cancer	6.95e-05	0.000288	CcSEcCtD
Bortezomib—Anaphylactic shock—Docetaxel—skin cancer	6.89e-05	0.000286	CcSEcCtD
Bortezomib—Oedema—Docetaxel—skin cancer	6.89e-05	0.000286	CcSEcCtD
Bortezomib—Dizziness—Temozolomide—skin cancer	6.85e-05	0.000284	CcSEcCtD
Bortezomib—Infection—Docetaxel—skin cancer	6.85e-05	0.000284	CcSEcCtD
Bortezomib—Nausea—Dactinomycin—skin cancer	6.8e-05	0.000282	CcSEcCtD
Bortezomib—Shock—Docetaxel—skin cancer	6.78e-05	0.000281	CcSEcCtD
Bortezomib—Nervous system disorder—Docetaxel—skin cancer	6.76e-05	0.00028	CcSEcCtD
Bortezomib—Pruritus—Fluorouracil—skin cancer	6.75e-05	0.00028	CcSEcCtD
Bortezomib—Thrombocytopenia—Docetaxel—skin cancer	6.75e-05	0.00028	CcSEcCtD
Bortezomib—Tachycardia—Docetaxel—skin cancer	6.72e-05	0.000279	CcSEcCtD
Bortezomib—Skin disorder—Docetaxel—skin cancer	6.69e-05	0.000278	CcSEcCtD
Bortezomib—Vomiting—Temozolomide—skin cancer	6.59e-05	0.000273	CcSEcCtD
Bortezomib—Anorexia—Docetaxel—skin cancer	6.57e-05	0.000272	CcSEcCtD
Bortezomib—Rash—Temozolomide—skin cancer	6.53e-05	0.000271	CcSEcCtD
Bortezomib—Diarrhoea—Fluorouracil—skin cancer	6.53e-05	0.000271	CcSEcCtD
Bortezomib—Dermatitis—Temozolomide—skin cancer	6.53e-05	0.000271	CcSEcCtD
Bortezomib—Headache—Temozolomide—skin cancer	6.49e-05	0.000269	CcSEcCtD
Bortezomib—Hypotension—Docetaxel—skin cancer	6.44e-05	0.000267	CcSEcCtD
Bortezomib—Dizziness—Fluorouracil—skin cancer	6.31e-05	0.000262	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Docetaxel—skin cancer	6.28e-05	0.00026	CcSEcCtD
Bortezomib—Insomnia—Docetaxel—skin cancer	6.23e-05	0.000258	CcSEcCtD
Bortezomib—Paraesthesia—Docetaxel—skin cancer	6.19e-05	0.000257	CcSEcCtD
Bortezomib—Nausea—Temozolomide—skin cancer	6.15e-05	0.000255	CcSEcCtD
Bortezomib—Dyspnoea—Docetaxel—skin cancer	6.14e-05	0.000255	CcSEcCtD
Bortezomib—Vomiting—Fluorouracil—skin cancer	6.07e-05	0.000252	CcSEcCtD
Bortezomib—Dyspepsia—Docetaxel—skin cancer	6.07e-05	0.000252	CcSEcCtD
Bortezomib—Rash—Fluorouracil—skin cancer	6.02e-05	0.00025	CcSEcCtD
Bortezomib—Dermatitis—Fluorouracil—skin cancer	6.01e-05	0.000249	CcSEcCtD
Bortezomib—Decreased appetite—Docetaxel—skin cancer	5.99e-05	0.000248	CcSEcCtD
Bortezomib—Headache—Fluorouracil—skin cancer	5.98e-05	0.000248	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Docetaxel—skin cancer	5.95e-05	0.000247	CcSEcCtD
Bortezomib—Fatigue—Docetaxel—skin cancer	5.94e-05	0.000246	CcSEcCtD
Bortezomib—Pain—Docetaxel—skin cancer	5.89e-05	0.000244	CcSEcCtD
Bortezomib—Constipation—Docetaxel—skin cancer	5.89e-05	0.000244	CcSEcCtD
Bortezomib—Feeling abnormal—Docetaxel—skin cancer	5.68e-05	0.000235	CcSEcCtD
Bortezomib—Nausea—Fluorouracil—skin cancer	5.67e-05	0.000235	CcSEcCtD
Bortezomib—Gastrointestinal pain—Docetaxel—skin cancer	5.63e-05	0.000234	CcSEcCtD
Bortezomib—Abdominal pain—Docetaxel—skin cancer	5.45e-05	0.000226	CcSEcCtD
Bortezomib—Body temperature increased—Docetaxel—skin cancer	5.45e-05	0.000226	CcSEcCtD
Bortezomib—Hypersensitivity—Docetaxel—skin cancer	5.08e-05	0.000211	CcSEcCtD
Bortezomib—Asthenia—Docetaxel—skin cancer	4.94e-05	0.000205	CcSEcCtD
Bortezomib—Pruritus—Docetaxel—skin cancer	4.87e-05	0.000202	CcSEcCtD
Bortezomib—Diarrhoea—Docetaxel—skin cancer	4.71e-05	0.000196	CcSEcCtD
Bortezomib—Dizziness—Docetaxel—skin cancer	4.56e-05	0.000189	CcSEcCtD
Bortezomib—Vomiting—Docetaxel—skin cancer	4.38e-05	0.000182	CcSEcCtD
Bortezomib—Rash—Docetaxel—skin cancer	4.34e-05	0.00018	CcSEcCtD
Bortezomib—Dermatitis—Docetaxel—skin cancer	4.34e-05	0.00018	CcSEcCtD
Bortezomib—Headache—Docetaxel—skin cancer	4.32e-05	0.000179	CcSEcCtD
Bortezomib—Nausea—Docetaxel—skin cancer	4.09e-05	0.00017	CcSEcCtD
Bortezomib—PSMB2—Cell Cycle—CDKN2A—skin cancer	3.9e-05	0.000293	CbGpPWpGaD
Bortezomib—PSMA1—Disease—TERT—skin cancer	3.86e-05	0.000289	CbGpPWpGaD
Bortezomib—PSMB8—Cell Cycle—CDKN2A—skin cancer	3.84e-05	0.000288	CbGpPWpGaD
Bortezomib—PSMD1—Disease—TERT—skin cancer	3.84e-05	0.000288	CbGpPWpGaD
Bortezomib—PSMD2—Disease—TERT—skin cancer	3.82e-05	0.000287	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—SHH—skin cancer	3.76e-05	0.000282	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—SHH—skin cancer	3.76e-05	0.000282	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—SHH—skin cancer	3.76e-05	0.000282	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—RASA1—skin cancer	3.73e-05	0.00028	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—RASA1—skin cancer	3.73e-05	0.00028	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—RASA1—skin cancer	3.73e-05	0.00028	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—SHH—skin cancer	3.7e-05	0.000278	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—RASA1—skin cancer	3.68e-05	0.000276	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—SMO—skin cancer	3.56e-05	0.000267	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—SMO—skin cancer	3.56e-05	0.000267	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—PTCH1—skin cancer	3.56e-05	0.000267	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—PTCH1—skin cancer	3.56e-05	0.000267	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—SMO—skin cancer	3.56e-05	0.000267	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—PTCH1—skin cancer	3.56e-05	0.000267	CbGpPWpGaD
Bortezomib—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—skin cancer	3.51e-05	0.000264	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—PTCH1—skin cancer	3.51e-05	0.000264	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—SMO—skin cancer	3.51e-05	0.000264	CbGpPWpGaD
Bortezomib—PSMB8—Cytokine Signaling in Immune system—HRAS—skin cancer	3.48e-05	0.000261	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—PTGER4—skin cancer	3.47e-05	0.00026	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—PTGER4—skin cancer	3.47e-05	0.00026	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—PTGER4—skin cancer	3.47e-05	0.00026	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—CSPG4—skin cancer	3.46e-05	0.000259	CbGpPWpGaD
Bortezomib—PSMA1—Metabolism—ERCC2—skin cancer	3.44e-05	0.000259	CbGpPWpGaD
Bortezomib—PSMD1—Metabolism—ERCC2—skin cancer	3.43e-05	0.000257	CbGpPWpGaD
Bortezomib—PSMA1—Adaptive Immune System—NRAS—skin cancer	3.43e-05	0.000257	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—PTGER4—skin cancer	3.42e-05	0.000257	CbGpPWpGaD
Bortezomib—PSMD2—Metabolism—ERCC2—skin cancer	3.41e-05	0.000256	CbGpPWpGaD
Bortezomib—PSMD1—Adaptive Immune System—NRAS—skin cancer	3.41e-05	0.000256	CbGpPWpGaD
Bortezomib—PSMD2—Adaptive Immune System—NRAS—skin cancer	3.39e-05	0.000255	CbGpPWpGaD
Bortezomib—PSMB5—Gene Expression—ERCC2—skin cancer	3.36e-05	0.000252	CbGpPWpGaD
Bortezomib—PSMB1—Gene Expression—ERCC2—skin cancer	3.36e-05	0.000252	CbGpPWpGaD
Bortezomib—PSMB2—Gene Expression—ERCC2—skin cancer	3.36e-05	0.000252	CbGpPWpGaD
Bortezomib—PSMB8—Cytokine Signaling in Immune system—IL6—skin cancer	3.33e-05	0.00025	CbGpPWpGaD
Bortezomib—PSMB8—Gene Expression—ERCC2—skin cancer	3.31e-05	0.000248	CbGpPWpGaD
Bortezomib—PSMB5—Disease—ERCC2—skin cancer	3.12e-05	0.000234	CbGpPWpGaD
Bortezomib—PSMB1—Disease—ERCC2—skin cancer	3.12e-05	0.000234	CbGpPWpGaD
Bortezomib—PSMB2—Disease—ERCC2—skin cancer	3.12e-05	0.000234	CbGpPWpGaD
Bortezomib—PSMB8—Disease—ERCC2—skin cancer	3.07e-05	0.000231	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—FOXO4—skin cancer	3.06e-05	0.00023	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—FOXO4—skin cancer	3.06e-05	0.00023	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—FOXO4—skin cancer	3.06e-05	0.00023	CbGpPWpGaD
Bortezomib—PSMA1—Disease—BRAF—skin cancer	3.05e-05	0.000229	CbGpPWpGaD
Bortezomib—PSMD1—Disease—BRAF—skin cancer	3.04e-05	0.000228	CbGpPWpGaD
Bortezomib—PSMD2—Disease—BRAF—skin cancer	3.02e-05	0.000227	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PLIN2—skin cancer	3.02e-05	0.000227	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—FOXO4—skin cancer	3.02e-05	0.000227	CbGpPWpGaD
Bortezomib—PSMA1—Adaptive Immune System—KRAS—skin cancer	2.95e-05	0.000221	CbGpPWpGaD
Bortezomib—PSMD1—Adaptive Immune System—KRAS—skin cancer	2.94e-05	0.00022	CbGpPWpGaD
Bortezomib—PSMB5—Disease—TERT—skin cancer	2.92e-05	0.000219	CbGpPWpGaD
Bortezomib—PSMB1—Disease—TERT—skin cancer	2.92e-05	0.000219	CbGpPWpGaD
Bortezomib—PSMB2—Disease—TERT—skin cancer	2.92e-05	0.000219	CbGpPWpGaD
Bortezomib—PSMD2—Adaptive Immune System—KRAS—skin cancer	2.92e-05	0.000219	CbGpPWpGaD
Bortezomib—PSMB8—Disease—TERT—skin cancer	2.88e-05	0.000216	CbGpPWpGaD
Bortezomib—PSMA1—Cell Cycle—TP53—skin cancer	2.86e-05	0.000215	CbGpPWpGaD
Bortezomib—PSMD1—Cell Cycle—TP53—skin cancer	2.85e-05	0.000214	CbGpPWpGaD
Bortezomib—PSMD2—Cell Cycle—TP53—skin cancer	2.83e-05	0.000213	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PLIN2—skin cancer	2.77e-05	0.000208	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—TERT—skin cancer	2.7e-05	0.000203	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—TERT—skin cancer	2.69e-05	0.000202	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—TERT—skin cancer	2.67e-05	0.000201	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—ERCC2—skin cancer	2.61e-05	0.000196	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—ERCC2—skin cancer	2.61e-05	0.000196	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—ERCC2—skin cancer	2.61e-05	0.000196	CbGpPWpGaD
Bortezomib—PSMB5—Adaptive Immune System—NRAS—skin cancer	2.6e-05	0.000195	CbGpPWpGaD
Bortezomib—PSMB1—Adaptive Immune System—NRAS—skin cancer	2.6e-05	0.000195	CbGpPWpGaD
Bortezomib—PSMB2—Adaptive Immune System—NRAS—skin cancer	2.6e-05	0.000195	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—ERCC2—skin cancer	2.57e-05	0.000193	CbGpPWpGaD
Bortezomib—PSMB8—Adaptive Immune System—NRAS—skin cancer	2.56e-05	0.000192	CbGpPWpGaD
Bortezomib—PSMA1—Adaptive Immune System—HRAS—skin cancer	2.51e-05	0.000188	CbGpPWpGaD
Bortezomib—PSMD1—Adaptive Immune System—HRAS—skin cancer	2.49e-05	0.000187	CbGpPWpGaD
Bortezomib—PSMD2—Adaptive Immune System—HRAS—skin cancer	2.48e-05	0.000186	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PLIN2—skin cancer	2.47e-05	0.000186	CbGpPWpGaD
Bortezomib—PSMA1—Disease—PTGS2—skin cancer	2.47e-05	0.000185	CbGpPWpGaD
Bortezomib—PSMD1—Disease—PTGS2—skin cancer	2.45e-05	0.000184	CbGpPWpGaD
Bortezomib—PSMD2—Disease—PTGS2—skin cancer	2.44e-05	0.000183	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—CSPG4—skin cancer	2.44e-05	0.000183	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—ENO2—skin cancer	2.35e-05	0.000176	CbGpPWpGaD
Bortezomib—PSMB5—Disease—BRAF—skin cancer	2.31e-05	0.000174	CbGpPWpGaD
Bortezomib—PSMB1—Disease—BRAF—skin cancer	2.31e-05	0.000174	CbGpPWpGaD
Bortezomib—PSMB2—Disease—BRAF—skin cancer	2.31e-05	0.000174	CbGpPWpGaD
Bortezomib—PSMB8—Disease—BRAF—skin cancer	2.28e-05	0.000171	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PLIN2—skin cancer	2.27e-05	0.000171	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PLIN2—skin cancer	2.25e-05	0.000169	CbGpPWpGaD
Bortezomib—PSMB5—Adaptive Immune System—KRAS—skin cancer	2.24e-05	0.000168	CbGpPWpGaD
Bortezomib—PSMB2—Adaptive Immune System—KRAS—skin cancer	2.24e-05	0.000168	CbGpPWpGaD
Bortezomib—PSMB1—Adaptive Immune System—KRAS—skin cancer	2.24e-05	0.000168	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—CSPG4—skin cancer	2.23e-05	0.000168	CbGpPWpGaD
Bortezomib—PSMB8—Adaptive Immune System—KRAS—skin cancer	2.2e-05	0.000165	CbGpPWpGaD
Bortezomib—PSMB5—Cell Cycle—TP53—skin cancer	2.17e-05	0.000163	CbGpPWpGaD
Bortezomib—PSMB1—Cell Cycle—TP53—skin cancer	2.17e-05	0.000163	CbGpPWpGaD
Bortezomib—PSMB2—Cell Cycle—TP53—skin cancer	2.17e-05	0.000163	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—BRAF—skin cancer	2.14e-05	0.000161	CbGpPWpGaD
Bortezomib—PSMB8—Cell Cycle—TP53—skin cancer	2.14e-05	0.00016	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—BRAF—skin cancer	2.13e-05	0.00016	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—BRAF—skin cancer	2.12e-05	0.000159	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—NRAS—skin cancer	2.08e-05	0.000156	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—NRAS—skin cancer	2.07e-05	0.000155	CbGpPWpGaD
Bortezomib—PSMA1—Metabolism—PTGS2—skin cancer	2.07e-05	0.000155	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—NRAS—skin cancer	2.06e-05	0.000155	CbGpPWpGaD
Bortezomib—PSMD1—Metabolism—PTGS2—skin cancer	2.06e-05	0.000154	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—TERT—skin cancer	2.05e-05	0.000154	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—TERT—skin cancer	2.05e-05	0.000154	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—TERT—skin cancer	2.05e-05	0.000154	CbGpPWpGaD
Bortezomib—PSMD2—Metabolism—PTGS2—skin cancer	2.05e-05	0.000154	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—TERT—skin cancer	2.02e-05	0.000151	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—CSPG4—skin cancer	1.99e-05	0.00015	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PLIN2—skin cancer	1.93e-05	0.000145	CbGpPWpGaD
Bortezomib—PSMA1—Disease—NRAS—skin cancer	1.92e-05	0.000144	CbGpPWpGaD
Bortezomib—PSMD1—Disease—NRAS—skin cancer	1.91e-05	0.000143	CbGpPWpGaD
Bortezomib—PSMD2—Disease—NRAS—skin cancer	1.9e-05	0.000143	CbGpPWpGaD
Bortezomib—PSMB1—Adaptive Immune System—HRAS—skin cancer	1.9e-05	0.000143	CbGpPWpGaD
Bortezomib—PSMB5—Adaptive Immune System—HRAS—skin cancer	1.9e-05	0.000143	CbGpPWpGaD
Bortezomib—PSMB2—Adaptive Immune System—HRAS—skin cancer	1.9e-05	0.000143	CbGpPWpGaD
Bortezomib—PSMB8—Adaptive Immune System—HRAS—skin cancer	1.87e-05	0.000141	CbGpPWpGaD
Bortezomib—PSMB1—Disease—PTGS2—skin cancer	1.87e-05	0.00014	CbGpPWpGaD
Bortezomib—PSMB5—Disease—PTGS2—skin cancer	1.87e-05	0.00014	CbGpPWpGaD
Bortezomib—PSMB2—Disease—PTGS2—skin cancer	1.87e-05	0.00014	CbGpPWpGaD
Bortezomib—PSMB8—Disease—PTGS2—skin cancer	1.84e-05	0.000138	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.84e-05	0.000138	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—CSPG4—skin cancer	1.83e-05	0.000138	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—CSPG4—skin cancer	1.82e-05	0.000136	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—KRAS—skin cancer	1.79e-05	0.000134	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—KRAS—skin cancer	1.78e-05	0.000134	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—KRAS—skin cancer	1.77e-05	0.000133	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—ENO2—skin cancer	1.66e-05	0.000124	CbGpPWpGaD
Bortezomib—PSMA1—Disease—KRAS—skin cancer	1.65e-05	0.000124	CbGpPWpGaD
Bortezomib—PSMD1—Disease—KRAS—skin cancer	1.64e-05	0.000123	CbGpPWpGaD
Bortezomib—PSMD2—Disease—KRAS—skin cancer	1.64e-05	0.000123	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—BRAF—skin cancer	1.62e-05	0.000122	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—BRAF—skin cancer	1.62e-05	0.000122	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—BRAF—skin cancer	1.62e-05	0.000122	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—BRAF—skin cancer	1.6e-05	0.00012	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—NRAS—skin cancer	1.58e-05	0.000118	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—NRAS—skin cancer	1.58e-05	0.000118	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—NRAS—skin cancer	1.58e-05	0.000118	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—PTGS2—skin cancer	1.57e-05	0.000118	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—PTGS2—skin cancer	1.57e-05	0.000118	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—PTGS2—skin cancer	1.57e-05	0.000118	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—NRAS—skin cancer	1.55e-05	0.000117	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CSPG4—skin cancer	1.55e-05	0.000117	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—PTGS2—skin cancer	1.54e-05	0.000116	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—HRAS—skin cancer	1.52e-05	0.000114	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—ENO2—skin cancer	1.52e-05	0.000114	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—HRAS—skin cancer	1.51e-05	0.000114	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—HRAS—skin cancer	1.51e-05	0.000113	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PLIN2—skin cancer	1.49e-05	0.000112	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—IL6—skin cancer	1.46e-05	0.000109	CbGpPWpGaD
Bortezomib—PSMB5—Disease—NRAS—skin cancer	1.45e-05	0.000109	CbGpPWpGaD
Bortezomib—PSMB1—Disease—NRAS—skin cancer	1.45e-05	0.000109	CbGpPWpGaD
Bortezomib—PSMB2—Disease—NRAS—skin cancer	1.45e-05	0.000109	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—IL6—skin cancer	1.45e-05	0.000109	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—IL6—skin cancer	1.44e-05	0.000108	CbGpPWpGaD
Bortezomib—PSMB8—Disease—NRAS—skin cancer	1.43e-05	0.000108	CbGpPWpGaD
Bortezomib—PSMA1—Disease—HRAS—skin cancer	1.4e-05	0.000105	CbGpPWpGaD
Bortezomib—PSMD1—Disease—HRAS—skin cancer	1.4e-05	0.000105	CbGpPWpGaD
Bortezomib—PSMD2—Disease—HRAS—skin cancer	1.39e-05	0.000104	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—ERCC2—skin cancer	1.36e-05	0.000102	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—KRAS—skin cancer	1.36e-05	0.000102	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—KRAS—skin cancer	1.36e-05	0.000102	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—KRAS—skin cancer	1.36e-05	0.000102	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—ENO2—skin cancer	1.35e-05	0.000102	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—NRAS—skin cancer	1.34e-05	0.000101	CbGpPWpGaD
Bortezomib—PSMA1—Disease—IL6—skin cancer	1.34e-05	0.000101	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—NRAS—skin cancer	1.34e-05	0.0001	CbGpPWpGaD
Bortezomib—PSMD1—Disease—IL6—skin cancer	1.34e-05	0.0001	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—KRAS—skin cancer	1.34e-05	0.0001	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—NRAS—skin cancer	1.33e-05	9.99e-05	CbGpPWpGaD
Bortezomib—PSMD2—Disease—IL6—skin cancer	1.33e-05	9.99e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.29e-05	9.72e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—KRAS—skin cancer	1.25e-05	9.4e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—KRAS—skin cancer	1.25e-05	9.4e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—KRAS—skin cancer	1.25e-05	9.4e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—ENO2—skin cancer	1.25e-05	9.35e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—ENO2—skin cancer	1.24e-05	9.27e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—KRAS—skin cancer	1.23e-05	9.26e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CSPG4—skin cancer	1.2e-05	9e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.19e-05	8.91e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—KRAS—skin cancer	1.16e-05	8.68e-05	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—HRAS—skin cancer	1.15e-05	8.65e-05	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—HRAS—skin cancer	1.15e-05	8.65e-05	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—HRAS—skin cancer	1.15e-05	8.65e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—KRAS—skin cancer	1.15e-05	8.64e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—KRAS—skin cancer	1.15e-05	8.6e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—HRAS—skin cancer	1.14e-05	8.53e-05	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—IL6—skin cancer	1.1e-05	8.28e-05	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—IL6—skin cancer	1.1e-05	8.28e-05	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—IL6—skin cancer	1.1e-05	8.28e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—IL6—skin cancer	1.09e-05	8.16e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—HRAS—skin cancer	1.06e-05	7.99e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—HRAS—skin cancer	1.06e-05	7.99e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—HRAS—skin cancer	1.06e-05	7.99e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.06e-05	7.95e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—ENO2—skin cancer	1.06e-05	7.92e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—HRAS—skin cancer	1.05e-05	7.87e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—TP53—skin cancer	1.03e-05	7.72e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—TP53—skin cancer	1.02e-05	7.68e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—NRAS—skin cancer	1.02e-05	7.64e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—NRAS—skin cancer	1.02e-05	7.64e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—NRAS—skin cancer	1.02e-05	7.64e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—IL6—skin cancer	1.02e-05	7.64e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—IL6—skin cancer	1.02e-05	7.64e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—IL6—skin cancer	1.02e-05	7.64e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—TP53—skin cancer	1.02e-05	7.64e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—NRAS—skin cancer	1e-05	7.54e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—IL6—skin cancer	1e-05	7.54e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—HRAS—skin cancer	9.83e-06	7.38e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—HRAS—skin cancer	9.78e-06	7.34e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—HRAS—skin cancer	9.74e-06	7.31e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	9.66e-06	7.25e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—ERCC2—skin cancer	9.62e-06	7.22e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—IL6—skin cancer	9.41e-06	7.06e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—IL6—skin cancer	9.36e-06	7.03e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—IL6—skin cancer	9.32e-06	7e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—ERCC2—skin cancer	8.82e-06	6.62e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—KRAS—skin cancer	8.76e-06	6.58e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—KRAS—skin cancer	8.76e-06	6.58e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—KRAS—skin cancer	8.76e-06	6.58e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—KRAS—skin cancer	8.64e-06	6.49e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	8.25e-06	6.2e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PTGS2—skin cancer	8.18e-06	6.14e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ENO2—skin cancer	8.15e-06	6.12e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—ERCC2—skin cancer	7.87e-06	5.91e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—TP53—skin cancer	7.79e-06	5.85e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—TP53—skin cancer	7.79e-06	5.85e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—TP53—skin cancer	7.79e-06	5.85e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—TP53—skin cancer	7.68e-06	5.77e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—HRAS—skin cancer	7.45e-06	5.59e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—HRAS—skin cancer	7.45e-06	5.59e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—HRAS—skin cancer	7.45e-06	5.59e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—HRAS—skin cancer	7.35e-06	5.51e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—ERCC2—skin cancer	7.24e-06	5.43e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—ERCC2—skin cancer	7.17e-06	5.39e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—IL6—skin cancer	7.13e-06	5.35e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—IL6—skin cancer	7.13e-06	5.35e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—IL6—skin cancer	7.13e-06	5.35e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—IL6—skin cancer	7.03e-06	5.28e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—ERCC2—skin cancer	6.13e-06	4.6e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PTGS2—skin cancer	5.77e-06	4.33e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PTGS2—skin cancer	5.29e-06	3.97e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ERCC2—skin cancer	4.73e-06	3.55e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PTGS2—skin cancer	4.72e-06	3.54e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PTGS2—skin cancer	4.34e-06	3.26e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PTGS2—skin cancer	4.3e-06	3.23e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PTGS2—skin cancer	3.68e-06	2.76e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PTGS2—skin cancer	2.84e-06	2.13e-05	CbGpPWpGaD
